Catamaran Bio develops allogeneic CAR-NK cell therapies using genetic engineering and synthetic biology to create off-the-shelf treatments for solid tumors and other cancers. Their TAILWIND® platform enables the efficient engineering and expansion of natural killer cells, addressing the need for accessible and potent cancer therapies.
Funding
$42M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LVFounders
Product
Problem
Solid tumors pose a significant challenge in cancer treatment due to their complex microenvironment and resistance to conventional therapies. Effective and accessible treatments are needed to overcome these limitations and improve patient outcomes.
Solution
Catamaran Bio is developing allogeneic CAR-NK cell therapies designed as off-the-shelf treatments for solid tumors and other cancers. The company leverages genetic engineering and synthetic biology to enhance the natural cancer-fighting properties of NK cells. Their TAILWIND® platform facilitates the efficient engineering, expansion, and processing of NK cells into potent CAR-NK cell therapy products. This approach aims to provide safe, accessible, and transformative cell therapies for a broader range of patients and cancer types. By harnessing the unique characteristics of NK cells, Catamaran Bio seeks to overcome the limitations of existing cancer treatments and improve patient outcomes.
Target Audience
The primary target audience includes cancer patients with solid tumors and other cancers, as well as healthcare providers seeking more effective and accessible treatment options.
Features
- TAILWIND® platform for efficient engineering and expansion of NK cells
- Allogeneic CAR-NK cell therapies for off-the-shelf treatment
- Non-viral cell engineering for enhanced safety and potency
- Targeting solid tumors and other cancers
- Genetically engineered NK cells with enhanced cancer-fighting properties